Behind the buzz and beyond the hype:
Our Nanowerk-exclusive feature articles
Posted: May 04, 2017
Nanotechnology vaccines in cancer immunotherapy
(Nanowerk Spotlight) Immunotherapy has become an important part of treating some types of cancer. It uses certain parts of a person's immune system to fight the cancer. Usually this is done by administering immune system components, such as man-made immune system proteins.
Tumors evade the immune system by suppressing its ability to recognize and kill cancer cells. The goal of immunotherapy is to normalize and harness the body’s immune system so that it can more effectively fight the tumors.
In recent years, nanotechnology has played an increasingly important role in pursuing efficient
vaccine delivery in cancer immunotherapy.
The article looks at how nanotechnology vaccines can efficiently codeliver subunit vaccines, including adjuvants and multiepitope antigens, into lymphoid organs and into antigen-presenting cells, and the intracellular release of vaccine and cross-presentation of antigens can be fine-tuned via nanovaccine engineering. Aside from peptide antigens, antigen-encoding mRNA for cancer immunotherapy delivered by nanovaccine are also discussed.
Schematic depiction of nanovaccine-based vaccine delivery for cancer immunotherapy. Nanovaccines can be loaded with both adjuvant and multiepitope antigens on the surface (as depicted) or inside nanocarriers. Locally administered nanovaccines efficiently codeliver adjuvant and tumor antigen to secondary lymphoid. (Reprinted with permission by American Chemical Society) (click on image to enlarge)
To execute nanovaccine-based cancer therapy, exogenous nanovaccines can be administered into the body to enable uptake by endogenous phagocytic cells (e.g., dendritic cells, macrophages, monocytes, neutrophils), stimulate innate and adaptive immune cells, and elicit immunity; alternatively, isolated immune cells (e.g., dendritic cells) can be treated with nanovaccines ex vivo, followed by injection of treated cells in vivo for immune modulation.
As the authors write, "chemically defined subunit vaccines can elicit antigen-specific T-cell responses and are relatively easy to manufacture on large scales. However, currently, subunit vaccines have shown limited therapeutic efficacy in humans, which is in part attributed to the poor efficiency of vaccine delivery."
Therefore, nanotechnologies that can efficiently deliver subunit vaccine to secondary lymphoid organs to improve the therapeutic efficacy of vaccines are promising avenues of treatment.
For example, nanovaccines can avoid the otherwise rapid dissemination into the blood circulation and can be drained efficiently into lymph nodes by the lymphatics, which provides a prolonged time window for the nanovaccine to interact with lymph node-residing lymphocytes.
Nanovaccines can also codeliver cancer antigen and adjuvant or multiepitope antigens to induce a broad anticancer T-cell response with minimal immune tolerance.
Further, nanovaccines can be internalized efficiently by antigen-presenting cells, which present antigen to T cells; inside antigen-presenting cells, the nanovaccine can be engineered precisely to release adjuvant and antigen at desired intracellular compartments for optimal cancer immunotherapy.
Nanotechnology vaccines are also expected to facilitate the evaluation and application of cancer therapeutic neoantigen and in vitro transcribed mRNA (IVT-mRNA) antigen, which are two classes of antigens that have recently been extensively explored for cancer immunotherapy.
The scientists point out that this IVT-mRNA vaccine is an emerging candidate enthusiastically pursued for cancer immunotherapy, yet the delivery of naked mRNA, like other therapeutic nucleic acids such as siRNA and plasmids, can be a daunting challenge.
Nanomaterials show promise in improving the efficiency of IVT-mRNA delivery by protecting mRNA from nuclease degradation, enhancing mRNA delivery to lymphoid organs, such as lymph nodes and spleens, and facilitating intracellular delivery of mRNA to antigen-presenting cells.
The authors conclude that "in small animals, a good number of nanovaccines have shown the ability to induce antitumor immunity and can be combined with many other therapeutic modalities for synergistic cancer therapy. It is expected that in the next few years, more types of nanovaccines can be manufactured on large scales and at good manufacturing practice (GMP) grade, and GMP-produced nanovaccines can be tested in humans for safety and therapeutic efficacy."